NovaBridge Biosciences (NASDAQ: NBP) is a Healthcare company (Biotechnology) with a market capitalization of $95M. The Maz Rating grades it against the other companies in its sector.
NovaBridge Biosciences's current Maz Rating and its five factor grades are for members: log in to see them.
At $0.82, NovaBridge Biosciences trades at 0.5x book value, with an EV/EBITDA of 1.7. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -1.4%, return on invested capital of -29.0% and a free cash flow yield of -37.3%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 7.64. Over the past 52 weeks the share price ranged from $0.75 to $5.19, with a beta of 1.71.
NovaBridge Biosciences does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of June 2026, NovaBridge Biosciences (NBP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 151.2% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 133.6% / 33% · Receivables / Mkt Cap (36m) 3.95% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 133.6% / 33.33% · Receivables / Mkt Cap (24m) 3.95% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 82.3% / 33.33% · Receivables / Avg Assets (4Q) 0.09% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 82.4% / 33.33% · (Cash+Recv) / Total Assets 84.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of June 2026, NovaBridge Biosciences (NBP) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. NovaBridge Biosciences is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
NovaBridge Biosciences reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated June 30, 2026 (Q2 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.